

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10564599
Filing Date		2006-01-13
First Named Inventor	M. Secretin	
Art Unit	Unknown	
Examiner Name	Unknown	
Attorney Docket Number	112701-702	

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/K.B./	1	5916621		1999-06-29	Guenther et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/K.B./	1	20030077255		2003-04-24	S. Hemant	
/K.B./	2	20030017192		2003-01-23	Hanny et al.	
/K.B./	3	20020004527		2002-01-10	O'Connor et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
/K.B./	1	EP1048226	EP		2000-11-02			<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10564599
Filing Date		2006-01-13
First Named Inventor	M. Secretin	
Art Unit	Unknown	
Examiner Name	Unknown	
Attorney Docket Number	112701-702	

/K.B./	2	EP1228707	EP		2002-08-07			<input type="checkbox"/>
/K.B./	3	EP0904784	EP		1999-03-31			<input type="checkbox"/>
/K.B./	4	WO 02/15719	WO		2002-02-28			<input type="checkbox"/>
/K.B./	5	WO 02/080276	WO		2002-08-08			<input type="checkbox"/>
	6	DE20202562	DE		2002-05-23	➔	Reference not in English	<input type="checkbox"/>
/K.B./	7	EP0880902	EP		1996-12-02		Abstract only- the rest of the reference is not in English	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
/K.B./	1	Ogata, T., "EFFECT OF BIFIDOBACTERIUM LONGUM BB536 YOGURT ADMINISTRATION ON THE INTESTINAL ENVIRONMENT OF HEALTHY ADULTS," Microbial Ecology in Health & Disease, (Vol. 11, No. 1, 1999), pp. 41-46	<input type="checkbox"/>
/K.B./	2	Grill, J.P., "BIFIDOBACTERIA AND PROBIOTIC EFFECTS: ACTION OF BIFIDOBACTERIUM SPECIES ON CONJUGATED BILE SALTS," Current Microbiology, (Vol. 31, No. 1, 1995), pp. 23-27	<input type="checkbox"/>
/K.B./	3	Isolauro, E., "PROBIOTICS IN THE MANAGEMENT OF ATOPIC ECZEMA," Clinical and Experimental Allergy, (Vol. 30, No. 1, 2000), pp. 1604-1610	<input type="checkbox"/>

/Kelly Bekker/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10584599
Filing Date		2006-01-13
First Named Inventor	M. Secretin	
Art Unit	Unknown	
Examiner Name	Unknown	
Attorney Docket Number	112701-702	

/K.B./	4	Saxelin, M., "LACTOBACILLUS GG - A HUMAN PROBIOTIC STRAIN WITH THOROUGH CLINICAL DOCUMENTATION," Food Reviews International, (Vol. 13, No. 2, 1997), pp. 293-313	<input type="checkbox"/>
/K.B./	5	Kalliomaki, M., "PROBIOTICS AND PREVENTION OF ATOPIC DISEASE: 4-YEAR FOLLOW-UP OF A RANDOMISED PLACEBO-CONTROLLED TRIAL," The Lancet, (Vol. 381, No. 9372, 2003), pp. 1869-1871	<input type="checkbox"/>
/K.B./	6	Matsumoto, M., "ADHESIVE PROPERTY OF BIFIBACTERIUM LACTIS LKM512 AND PREDOMINANT BACTERIA OF INTESTINAL MICROFLORA TO HUMAN INTESTINAL MUCIN," Current Microbiology, (Vol. 44, No. 3, 2002), pp. 212-215	<input type="checkbox"/>
/K.B./	7	Bruck, W.M., "A TWO-STAGE CONTINUOUS CULTURE SYSTEM TO STUDY THE EFFECT OF SUPPLEMENTAL ALPHA-LACTALBUMIN AND GLYCOMACROPEPTIDE ON MIXED CULTURES OF HUMAN GUT BACTERIA CHALLENGED WITH ENTEROPATHOGENIC ESCHERICHIA COLI AND SALMONELLA SEROTYPE TYPHIMURIUM," Journal of Applied Microbiology, (Vol. 95, No. 1, 2003), pp. 44-53	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Kelly Bekker/	Date Considered	03/04/2009
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV/ or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****(Not for submission under 37 CFR 1.99)**

Application Number	10564599
Filing Date	2006-01-13
First Named Inventor	M. Secretin
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	112701-702

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Robert M. Barrett/	Date (YYYY-MM-DD)	2006-11-06
Name/Print	Robert M. Barrett	Registration Number	30142

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.